Edinburgh, Scotland-When used by the same operators in a single center, shockwave lithotriptors of different power generators provide comparable results and have similar complication rates in the treatment of renal stones, urologists at a Scottish stone center reported at the AUA annual meeting.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.